ArticleFrontiers in immunology2025
Identification and validation of icaritin-associated prognostic genes in hepatocellular carcinoma through network pharmacology, bioinformatics analysis, and cellular experiments.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Network Pharmacology Analysis of Glycyrrhetinic Acid in Metabolic Dysfunction-Associated Steatotic Liver Disease.Metabolites · 2026Article
- Efficacy analysis of icaritin combined with transarterial chemoembolization in hepatocellular carcinoma stratified by different child-pugh classes.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) is a key global health issue, marked by poor clinical outcomes and lower survival rates. Icaritin (ICT), a bioactive compound derived from traditional Chinese medicine, has shown promising multi-target antitumor properties and potential clinical benefits in the treatment of HCC; however, its precise mechanisms of action remain insufficiently understood. Therefore, this study adopted an integrative strategy that combined bioinformatics analysis, experimental validation, and network pharmacology to systematically explore the prognostic and therapeutic relevance of ICT-associated genes. Methods: Initially, potential targets of ICT and HCC-associated genes were identified through extensive database screening, and the overlapping candidates were further determined using WGCNA and differential expression analysis. These core intersecting genes were subsequently refined via four complementary machine learning algorithms, KM survival analysis and LASSO Cox regression to establish a prognostic risk score model with predictive value. Additionally, molecular docking and dynamics simulations were performed to evaluate the binding stability between ICT and these targets. Finally, Results: We identified thirty-five overlapping targets between ICT and HCC, and functional enrichment analysis showed that these genes are primarily implicated in cell cycle regulation and glycolytic pathways, highlighting potential mechanisms through which ICT exerts its antitumor effects. By integrating multiple machine learning approaches, KM survival analysis and LASSO Cox regression, we developed a four-gene prognostic model that successfully stratified HCC patients into higher- and lower-risk groups. Molecular docking and molecular dynamics simulations demonstrated that ICT binds stably to core targets, supporting its potential role in modulating disease progression. Conclusion: Modulation of ICT-targeted genes was found to effectively suppress HCC progression, underscoring their potential value as prognostic biomarkers and ideal therapeutic targets for the treatment of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.